StreetInsider.com News Articles

AC Immune reports positive TDP-43 tracer data in ALS patients

Fri, 22 May 2026 07:00:37 -0400

AC Immune SA (NASDAQ: ACIU) announced preliminary Phase 1 data showing its TDP-43 PET tracer ACI-19626 demonstrated increased uptake in brain regions of patients with amyotrophic lateral sclerosis compared to healthy controls.

The data presented at the 2026 TDP43 Summit in Madison, Wisconsin, showed tracer uptake was higher in the brain stem and precentral gyrus, areas where TDP-43 pathology typically accumulates based on post-mortem studies. The company previously reported that ACI-19626 detected TDP-43 pathology in patients with genetic frontotemporal dementia.

The ongoing Phase 1 trial has two parts. Part 1, investigating ACI-19626 in healthy volunteers and patients with genetic FTD, has been

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Fri, 22 May 2026 07:00:00 -0400

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS)
Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD)
Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases

Lausanne, Switzerland, May 22, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Fri, 22 May 2026 07:00:00 -0400

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS)
Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD)
Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases

Form 4 AC Immune SA For: May 15 Filed by: Pfeifer Andrea

Mon, 18 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260518/26514235.html

Form 4 AC Immune SA For: May 15 Filed by: Pfeifer Andrea

Mon, 18 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260518/26514235.html

Form 144 AC Immune SA Filed by: Pfeifer Andrea

Fri, 15 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26506321.html

Form 144 AC Immune SA Filed by: Pfeifer Andrea

Fri, 15 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26506321.html

Form 6-K AC Immune SA For: May 15

Fri, 15 May 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26500662.html

Form 6-K AC Immune SA For: May 15

Fri, 15 May 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26500662.html

Form 6-K AC Immune SA For: May 12

Tue, 12 May 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260512/26473563.html

Form 6-K AC Immune SA For: May 12

Tue, 12 May 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260512/26473563.html

AC Immune CEO Dr Andrea Pfeifer to retire after 23 years

Tue, 12 May 2026 07:00:52 -0400

AC Immune SA (NASDAQ: ACIU) announced that co-founder and Chief Executive Officer Dr Andrea Pfeifer will retire from her position at the company's upcoming Annual General Meeting after 23 years with the biopharmaceutical company.

Board Chair Dr Martin Zügel will serve as interim CEO while the company searches for a permanent successor. Dr Pfeifer will transition to roles as Advisor, Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board.

"It has been a great honor to serve as CEO of AC Immune together with so many dedicated and brilliant colleagues over the years," Dr Pfeifer said in

AC Immune CEO Dr Andrea Pfeifer to retire after 23 years

Tue, 12 May 2026 07:00:52 -0400

"It has been a great honor to serve as CEO of AC Immune together with so many dedicated and brilliant colleagues over the years," Dr Pfeifer said in

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Tue, 12 May 2026 07:00:00 -0400

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure
Board Chair, Martin Zügel, MD, to be appointed interim CEO
Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board
Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships
Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones

Lausanne, Switzerland, 12 May 2026 --

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Tue, 12 May 2026 07:00:00 -0400

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure
Board Chair, Martin Zügel, MD, to be appointed interim CEO
Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board
Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships
Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones

Lausanne, Switzerland, 12 May 2026 --

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Tue, 12 May 2026 07:00:00 -0400

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure
Board Chair, Martin Zügel, MD, to be appointed interim CEO
Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board
Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships
Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones

Lausanne, Switzerland, 12 May 2026 --

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Tue, 12 May 2026 07:00:00 -0400

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure
Board Chair, Martin Zügel, MD, to be appointed interim CEO
Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board
Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships
Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones

Lausanne, Switzerland, 12 May 2026 --

AC Immune SA (ACIU) Reports Q1 Loss of $0.15

Thu, 30 Apr 2026 07:10:15 -0400

AC Immune SA (NASDAQ: ACIU) reported Q1 EPS of ($0.15). Revenue for the quarter came in at $1.12 million versus the consensus estimate of $404.63 thousand.

For earnings history and earnings-related data on AC Immune SA (ACIU) click here.

Form 6-K AC Immune SA For: Apr 30

Thu, 30 Apr 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260430/26400464.html

Form 6-K AC Immune SA For: Apr 30

Thu, 30 Apr 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260430/26400464.html

AC Immune First Quarter 2026 Financial and Corporate Updates

Thu, 30 Apr 2026 07:05:00 -0400